South Korean biopharmaceutical company GC Biopharma (KRX: 006280) announced on Wednesday that its US subsidiary, ABO Holdings, has received US Food and Drug Administration (FDA) approval for its plasma collection centre in Calexico, California.

The approval follows GC Biopharma's recent acquisition of ABO Holdings in January 2025, a strategic move aimed at supporting the long-term revenue potential of ALYGLO, its immune globulin intravenous product, which was recently launched in the US market.

With this authorisation, ABO Holdings now operates six plasma collection centres across California, Utah, and New Jersey. The company plans to intensify donor recruitment efforts in the second quarter to support expanded operations.

ABO Holdings is also constructing two additional plasma centres in Texas, with FDA approval targeted by 2027.

GC Biopharma anticipates that its source plasma business will enter into a phase of gradual growth in the latter half of 2025.